Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

The adoptive transfer of T lymphocytes reprogrammed to target tumour cells has
demonstrated potential for treatment of various cancers,,,,,–. However, little is known about …

Cuproptosis is a new cell death that depends on copper (Cu) ionophores to transport Cu into
cancer cells, which induces cell death. However, existing Cu ionophores are small …

The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge
for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen …

Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Immune checkpoint blockade, which blocks inhibitory signals of T cell activation, has shown
tremendous success in treating cancer, although success still remains limited to a fraction of …

Cytotoxic T cells are important effectors of anti-tumor immunity. While tumor killing is
ascribed to CD8+ T cell function, pre-clinical and clinical studies have identified intra …

Interactions between T cell receptors (TCRs) and their cognate tumour antigens are central
to antitumour immune responses,–; however, the relationship between phenotypic …

Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …